<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JBX</journal-id>
<journal-id journal-id-type="hwp">spjbx</journal-id>
<journal-id journal-id-type="nlm-ta">J Biomol Screen</journal-id>
<journal-title>Journal of Biomolecular Screening</journal-title>
<issn pub-type="ppub">1087-0571</issn>
<issn pub-type="epub">1552-454X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1087057111416659</article-id>
<article-id pub-id-type="publisher-id">10.1177_1087057111416659</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Development of Homogeneous Nonradioactive Methyltransferase and Demethylase Assays Targeting Histone H3 Lysine 4</article-title>
</title-group>
<contrib-group content-type="issue">
<contrib contrib-type="guest-editor">
<name><surname>Heightman</surname><given-names>Tom</given-names></name>
</contrib>
<contrib contrib-type="guest-editor">
<name><surname>Pope</surname><given-names>Andrew</given-names></name>
</contrib>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Gauthier</surname><given-names>Nancy</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Caron</surname><given-names>Mireille</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Pedro</surname><given-names>Liliana</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Arcand</surname><given-names>Mathieu</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Blouin</surname><given-names>Julie</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Labonté</surname><given-names>Anne</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Normand</surname><given-names>Claire</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Paquet</surname><given-names>Valérie</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Rodenbrock</surname><given-names>Anja</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Roy</surname><given-names>Marjolaine</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Rouleau</surname><given-names>Nathalie</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Beaudet</surname><given-names>Lucille</given-names></name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Padrós</surname><given-names>Jaime</given-names></name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Rodriguez-Suarez</surname><given-names>Roberto</given-names></name>
</contrib>
<aff id="aff1-1087057111416659">PerkinElmer, Montreal, Quebec, Canada</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1087057111416659">Roberto Rodriguez-Suarez, PhD, and Jaime Padrós, PhD, PerkinElmer, 1744 William Street, Suite 600, Montreal, Quebec, Canada, H3J 1R4. E-mail: <email>Roberto.Rodriguez-Suarez@perkinelmer.com</email> and <email>Jaime.Padros@perkinelmer.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2012</year>
</pub-date>
<volume>17</volume>
<issue>1</issue>
<issue-title>Special Issue: Epigenetic-Targeted Drug Discovery, Part II</issue-title>
<fpage>49</fpage>
<lpage>58</lpage>
<history>
<date date-type="received">
<day>29</day>
<month>4</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>3</day>
<month>6</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>6</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 Society for Laboratory Automation and Screening</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Society for Laboratory Automation and Screening</copyright-holder>
</permissions>
<abstract>
<p>Histone posttranslational modifications are among the epigenetic mechanisms that modulate chromatin structure and gene transcription. Histone methylation and demethylation are dynamic processes controlled respectively by histone methyltransferases (HMTs) and demethylases (HDMs). Several HMTs and HDMs have been implicated in cancer, inflammation, and diabetes, making them attractive targets for drug therapy. Hence, the discovery of small-molecule modulators for these two enzyme classes has drawn significant attention from the pharmaceutical industry. Herein, the authors describe the development and optimization of homogeneous LANCE <italic>Ultra</italic> and AlphaLISA antibody-based assays for measuring the catalytic activity of two epigenetic enzymes acting on lysine 4 of histone H3: SET7/9 methyltransferase and LSD1 demethylase. Both the SET7/9 and LSD1 assays were designed as signal-increase assays using biotinylated peptides derived from the N-terminus of histone H3. In addition, the SET7/9 assay was demonstrated using full-length histone H3 protein as substrate in the AlphaLISA format. Optimized assays in 384-well plates are robust (Z′ factors ≥0.7) and sensitive, requiring only nanomolar concentrations of enzyme and substrate. All assays allowed profiling of known SET7/9 and LSD1 inhibitors. The results demonstrate that the optimized LANCE <italic>Ultra</italic> and AlphaLISA assay formats provide a relevant biochemical screening approach toward the identification of small-molecule inhibitors of HMTs and HDMs that could lead to novel epigenetic therapies.</p>
</abstract>
<kwd-group>
<kwd>epigenetics</kwd>
<kwd>SET7/9</kwd>
<kwd>LSD1</kwd>
<kwd>methyltransferase</kwd>
<kwd>demethylase</kwd>
<kwd>LANCE</kwd>
<kwd>TR-FRET</kwd>
<kwd>AlphaLISA</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1087057111416659" sec-type="intro">
<title>Introduction</title>
<p>Posttranslational modifications on histone proteins have been shown to play important roles in the regulation of chromatin structure and gene expression.<sup><xref ref-type="bibr" rid="bibr1-1087057111416659">1</xref></sup> The reversible nature of histone covalent modifications or “marks,”<sup><xref ref-type="bibr" rid="bibr2-1087057111416659">2</xref></sup> along with the deregulation of histone-modifying enzymes observed in diseased states such as cancer<sup><xref ref-type="bibr" rid="bibr3-1087057111416659">3</xref></sup> and neuropathologies,<sup><xref ref-type="bibr" rid="bibr4-1087057111416659">4</xref></sup> has promoted this enzyme group to an attractive class of drug targets.<sup><xref ref-type="bibr" rid="bibr5-1087057111416659">5</xref></sup></p>
<p>SET7/9 (KMT7), SMYD3, and members of the MLL (KMT2) protein family are histone methyltransferases that, together with LSD1 demethylase (KDM1), are known to affect the methylation level of histone H3 on the lysine 4 (H3K4) residue (reviewed by Ruthenburg et al.<sup><xref ref-type="bibr" rid="bibr6-1087057111416659">6</xref></sup>). Although methylation of H3K4 by SET7/9 and MLL has been linked to active transcription,<sup><xref ref-type="bibr" rid="bibr7-1087057111416659">7</xref>–<xref ref-type="bibr" rid="bibr9-1087057111416659">9</xref></sup> demethylation elicited by LSD1 in association with the CoREST complex was suggested to repress gene expression.<sup><xref ref-type="bibr" rid="bibr10-1087057111416659">10</xref></sup> SET7/9 contains an evolutionary conserved SET-domain that uses S-adenosyl-L-methionine (SAM, or AdoMet) as a co-substrate to catalyze the methylation of lysine.<sup><xref ref-type="bibr" rid="bibr7-1087057111416659">7</xref>,<xref ref-type="bibr" rid="bibr8-1087057111416659">8</xref></sup> Unlike most other SET proteins that catalyze the addition of up to three methyl groups, SET7/9 catalyzes the transfer of a single methyl group to the unmodified H3K4 residue and is thus referred to as a histone lysine mono-methyltransferase.<sup><xref ref-type="bibr" rid="bibr11-1087057111416659">11</xref></sup> On the other hand, LSD1 belongs to the flavin adenine dinucleotide (FAD)–dependent amine oxidase superfamily and specifically catalyzes the demethylation of mono- or dimethylated H3K4 residues with the concomitant formation of hydrogen peroxide and formaldehyde.<sup><xref ref-type="bibr" rid="bibr10-1087057111416659">10</xref></sup> In addition to being a repressor of transcription when associated with CoREST, LSD1 can also act as a transcriptional coactivator when complexed with the androgen receptor by demethylating mono- or dimethylated histone H3 lysine 9 residues.<sup><xref ref-type="bibr" rid="bibr12-1087057111416659">12</xref></sup> Both SET7/9 and LSD1 have been associated with disease: SET7/9 with inflammatory disorders and diabetes<sup><xref ref-type="bibr" rid="bibr13-1087057111416659">13</xref></sup> and LSD1 with various types of cancer,<sup><xref ref-type="bibr" rid="bibr14-1087057111416659">14</xref></sup> making these two enzymes potential targets for therapeutic intervention.</p>
<p>Several methodological approaches have been used for quantifying the activity of histone methyltransferases (HMTs) and histone demethylases (HDMs), including radiometric assays,<sup><xref ref-type="bibr" rid="bibr8-1087057111416659">8</xref>,<xref ref-type="bibr" rid="bibr15-1087057111416659">15</xref>,<xref ref-type="bibr" rid="bibr16-1087057111416659">16</xref></sup> enzyme-linked immunoassays,<sup><xref ref-type="bibr" rid="bibr17-1087057111416659">17</xref></sup> mass spectrometry,<sup><xref ref-type="bibr" rid="bibr10-1087057111416659">10</xref></sup> and enzyme-coupled detection of reaction by-products such as S-adenosyl-homocysteine (SAH, or AdoHcy),<sup><xref ref-type="bibr" rid="bibr18-1087057111416659">18</xref></sup> formaldehyde,<sup><xref ref-type="bibr" rid="bibr10-1087057111416659">10</xref></sup> or hydrogen peroxide.<sup><xref ref-type="bibr" rid="bibr19-1087057111416659">19</xref></sup> These methods suffer from drawbacks such as low throughput, lack of selectivity, high enzyme and peptide consumption, multiple wash steps, generation of hazardous waste, requirement for expensive equipment, or artifacts associated with the use of enzyme-coupled assays. The nonradioactive homogeneous LANCE <italic>Ultra</italic> and Alpha (AlphaScreen and AlphaLISA) platforms (<xref ref-type="fig" rid="fig1-1087057111416659"><bold>Fig. 1</bold></xref>), based respectively on time-resolved fluorescence resonance energy transfer (TR-FRET)<sup><xref ref-type="bibr" rid="bibr20-1087057111416659">20</xref></sup> and luminescent oxygen channeling assays,<sup><xref ref-type="bibr" rid="bibr21-1087057111416659">21</xref></sup> do not share these limitations and are now firmly established for the development and validation of high-throughput screening (HTS) campaigns.<sup><xref ref-type="bibr" rid="bibr22-1087057111416659">22</xref>,<xref ref-type="bibr" rid="bibr23-1087057111416659">23</xref></sup> In this regard, the AlphaScreen technology has been recently employed with success in the development of HTS assays for two epigenetic enzymes, G9a methyltransferase<sup><xref ref-type="bibr" rid="bibr24-1087057111416659">24</xref></sup> and JMJD2E demethylase.<sup><xref ref-type="bibr" rid="bibr25-1087057111416659">25</xref></sup></p>
<fig id="fig1-1087057111416659" position="float">
<label>Figure 1.</label>
<caption>
<p>Schematic representation of LANCE <italic>Ultra</italic> and AlphaLISA epigenetic assays. (<bold>A</bold>) Enzymatic assays using a biotinylated histone H3-derived peptide as substrate. In the first step, the enzyme modifies the substrate in the presence of the required cofactor to generate the reaction product; product detection can then be performed using LANCE <italic>Ultra</italic> or AlphaLISA antibody-based reagents directed against the mark of interest. In the LANCE <italic>Ultra</italic> setup (<bold>A</bold>, left), capture of the biotinylated reaction product by a europium-labeled antimark antibody (Eu-Ab, donor) and U<italic>Light</italic>-streptavidin (U<italic>Light</italic>-SA, acceptor) brings into close proximity donor and acceptor dye-bearing partners. Irradiation of complexed partners at 320 to 340 nm allows time-resolved fluorescence resonance energy transfer (TR-FRET) to occur between the europium-labeled antibody and the U<italic>Light</italic>-streptavidin, giving rise to light emission detected at 665 nm. In the AlphaLISA setup using a biotinylated peptide substrate (<bold>A</bold>, right), the reaction product is captured by streptavidin (SA) donor beads and anti-mark acceptor beads. Irradiation of complexed partners at 680 nm initiates in SA donor beads the production of singlet oxygen (<sup>1</sup>O<sub>2</sub>) molecules that reach the acceptor beads in proximity to generate a cascade of energy transfer reactions culminating in an amplified light emission detected at 615 nm. (<bold>B</bold>) Enzymatic assay using a full-length histone H3 substrate. A biotinylated antihistone H3 (C-ter) antibody is used for the capture of the full-length H3 protein by SA donor beads. For both LANCE <italic>Ultra</italic> and AlphaLISA assay setups, the intensity of emitted light is proportional to the level of substrate modification.</p>
</caption>
<graphic xlink:href="10.1177_1087057111416659-fig1.tif"/></fig>
<p>Using LANCE <italic>Ultra</italic> and AlphaLISA technologies, we undertook the development of sensitive and selective biochemical assays for measuring the activity of SET7/9 and LSD1 enzymes in a signal-increase mode. With both technologies, synthetic biotinylated peptides derived from the N-terminus of histone H3 (residues 1–21) were used as substrates (<xref ref-type="fig" rid="fig1-1087057111416659"><bold>Fig. 1A</bold></xref>). Furthermore, taking advantage of the AlphaLISA platform flexibility, we developed a SET7/9 assay using a full-length histone H3 protein substrate (<xref ref-type="fig" rid="fig1-1087057111416659"><bold>Fig. 1B</bold></xref>). In all cases, the methylation state of histone H3K4 residues was interrogated through the use of specific antibodies detecting either methylated or unmethylated H3K4 residues.</p>
</sec>
<sec id="section2-1087057111416659" sec-type="materials|methods">
<title>Materials and Methods</title>
<p>All biotinylated peptides, including substrate peptides histone H3 (1-21) (cat. 61702) and Lys4(me1)-histone H3 (1–21) (cat. 64355), were purchased from AnaSpec (Fremont, CA), whereas recombinant full-length histone H3 substrate (C110A) (cat. 31207) and modified positive controls were from Active Motif (Carlsbad, CA). S-(5′-adenosyl)-L-methionine chloride (cat. A7007), S-(5′-adenosyl)-L-homocysteine (cat. A9384), sinefungin (cat. S7559), trans-2-phenylcyclopropylamine (tranylcypromine; cat. P8511), and poly-L-lysine (cat. P1399) were purchased from Sigma-Aldrich (St. Louis, MO). Recombinant human SET7/9 methyltransferase (cat. ALX-201-178-C100) and LSD1 demethylase (cat. 50100) were purchased from Enzo Life Sciences International, Inc. (Plymouth Meeting, PA) and BPS Bioscience, Inc. (San Diego, CA), respectively. All other reagents were from PerkinElmer (Waltham, MA) unless otherwise stated. For LANCE <italic>Ultra</italic> assays, these included europium (Eu)–labeled anti-H3K4me1-2 (cat. TRF0402) and anti-unmodified H3K4 (cat. TRF0404) antibodies, U<italic>Light</italic>-labeled Streptavidin (U<italic>Light</italic>-SA; cat. TRF0102), and 10× LANCE Detection Buffer (cat. CR97-100). For AlphaLISA assays, reagents included anti-H3K4me1-2 (cat. AL116) and anti-unmodified H3K4 (cat. AL119) acceptor beads, streptavidin (SA) donor beads (cat. 6760002), biotinylated anti-H3 (C-ter) antibody (cat. AL118), and 5× Epigenetics Buffer 1 Kit (cat. AL008). Assays for both technologies were performed in white opaque OptiPlate 384-well microplates (cat. 6007290) using TopSeal-A sealing film (cat. 6005185). All steps using streptavidin donor beads were performed under subdued laboratory lighting (&lt;100 lux) using green filters (Roscolux filters #389) from Rosco (Stamford, CT) to avoid photo-depleting the beads. Plates were read on an EnVision Multilabel Plate Reader (PerkinElmer) in TR-FRET or Alpha mode according to the technology used.</p>
<sec id="section3-1087057111416659">
<title>LANCE <italic>Ultra</italic> enzymatic assays</title>
<p>LANCE <italic>Ultra</italic> SET7/9 and LSD1 assays were developed using a biotinylated histone H3-derived peptide (residues 1–21) as substrate. SET7/9 methyltransferase reactions were carried out in 50 mM Tris-HCl (pH 8.8) supplemented with 5 mM MgCl<sub>2</sub>, 1 mM dithiothreitol (DTT), and 0.01% Tween-20 and were initiated by the addition of a mix of biotinylated histone H3 peptide and SAM cofactor. LSD1 demethylase reactions were carried out in 50 mM Tris-HCl (pH 9.0) supplemented with 50 mM NaCl, 1 mM DTT, and 0.01% Tween-20 and were initiated by the addition of biotinylated H3K4me1 peptide substrate. All enzymatic reactions were performed for a fixed period of time at room temperature in a 10-µL volume (see <xref ref-type="table" rid="table1-1087057111416659"><bold>Table 1</bold></xref> for details on experimental conditions).</p>
<table-wrap id="table1-1087057111416659" position="float">
<label>Table 1.</label>
<caption>
<p>Optimized Conditions for SET7/9 Methyltransferase and LSD1 Demethylase Assays</p>
</caption>
<graphic alternate-form-of="table1-1087057111416659" xlink:href="10.1177_1087057111416659-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Technology</th>
<th align="center">Enzyme (Concentration)</th>
<th align="center">Substrate (Concentration)</th>
<th align="center">Cofactor (Concentration)</th>
<th align="center">Reaction Time, min</th>
<th align="center">Antimark Reagent</th>
</tr>
</thead>
<tbody>
<tr>
<td>LANCE <italic>Ultra</italic></td>
<td>SET7/9 (5 nM)</td>
<td>H3 peptide (200 nM)</td>
<td>SAM (300 nM)</td>
<td>60</td>
<td>Eu-anti-H3K4me1-2</td>
</tr>
<tr>
<td/>
<td>LSD1 (2 nM)</td>
<td>H3K4me1 peptide (200 nM)</td>
<td align="center">—</td>
<td>60</td>
<td>Eu-anti-unmodified H3K4</td>
</tr>
<tr>
<td>AlphaLISA</td>
<td>SET7/9 (1 nM)</td>
<td>H3 peptide (50 nM)</td>
<td>SAM (100 nM)</td>
<td>30</td>
<td>Anti-H3K4me1-2 acceptor beads</td>
</tr>
<tr>
<td/>
<td>SET7/9 (0.3 nM)</td>
<td>Full-length histone H3 (300 nM)</td>
<td>SAM (10 µM)</td>
<td>10</td>
<td>Anti-H3K4me1-2 acceptor beads</td>
</tr>
<tr>
<td/>
<td>LSD1 (2 nM)</td>
<td>H3K4me1 peptide (80 nM)</td>
<td align="center">—</td>
<td>60</td>
<td>Anti-unmodified H3K4 acceptor beads</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1087057111416659">
<p>SAM, S-adenosyl-L-methionine.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>SET7/9 methyltransferase reactions were stopped by adding a mixture of Eu-labeled anti-H3K4me1-2 antibody and U<italic>Light</italic>-SA prepared in 1× LANCE Detection Buffer. LSD1 demethylase reactions were stopped by the addition of 300 µM tranylcypromine prepared in 1× LANCE Detection Buffer and incubated for 5 min before the addition of a mixture of Eu-labeled anti-unmodified H3K4 antibody and U<italic>Light</italic>-SA. For both assays, Eu-labeled antibody and U<italic>Light</italic>-SA were used at final concentrations of 2 nM and 50 nM, respectively (total assay volume of 20 µL). Capture of the reaction products by the Eu-labeled antibodies and U<italic>Light</italic>-SA was allowed to proceed for 60 min at room temperature before measuring TR-FRET signal (excitation at 320 nm, emission at 615 and 665 nm, delay time 50 µs, window time 100 µs).</p>
</sec>
<sec id="section4-1087057111416659">
<title>AlphaLISA enzymatic assays</title>
<p>AlphaLISA SET7/9 assays were developed using two different substrates: a biotinylated histone H3-derived peptide (residues 1–21) and a recombinant full-length histone H3 protein substrate. The AlphaLISA LSD1 assay was developed using a biotinylated histone H3K4me1 (1–21) peptide substrate.</p>
<sec id="section5-1087057111416659">
<title>SET7/9 and LSD1 assays with biotinylated histone H3 peptide substrates</title>
<p>AlphaLISA SET7/9 methyltransferase and LSD1 demethylase reactions were run at room temperature in a 10-µL volume under conditions identical to those described for the LANCE <italic>Ultra</italic> assays. The enzymatic reactions were stopped by the addition of antibody-acceptor beads diluted in 1× Epigenetics Buffer 1. Anti-H3K4me1-2 acceptor beads were added to the SET7/9 reactions and anti-unmodified H3K4 acceptor beads to the LSD1 reactions. After 60 min at room temperature, SA donor beads prepared in 1× Epigenetics Buffer 1 were added, and the capture of the reaction product was allowed to proceed for an additional 30 min at room temperature before detecting the Alpha signal. For both assays, acceptor and SA donor beads were used at a final concentration of 20 µg/mL (total assay volume of 25 µL).</p>
</sec>
<sec id="section6-1087057111416659">
<title>SET7/9 assay using a recombinant histone H3 protein substrate</title>
<p>SET7/9 reactions using a recombinant full-length histone H3 protein as substrate were conducted at room temperature in a 10-µL volume under the conditions described before for the biotinylated peptide substrate.</p>
<p>Methyltransferase reactions were stopped by the addition of 5 µL of high salt buffer consisting of 50 mM Tris-HCl (pH 7.4), 1 M NaCl, 0.1% Tween-20, and 0.3% poly-L-lysine. After 15 min at room temperature, capture of the reaction product was initiated by the addition of a mixture of anti-H3K4me1-2 acceptor beads and biotinylated antihistone H3 (C-ter) antibody. SA donor beads were added 60 min later, and reactions were incubated for an additional 30 min before detection of the Alpha signal. Alpha beads and biotinylated antihistone H3 (C-ter) antibody were used at a final concentration of 20 µg/mL and 1 nM, respectively (total assay volume of 25 µL). All detection reagents were prepared in a detection buffer containing 50 mM Tris-HCl (pH 7.4), 300 mM NaCl, 0.1% Tween-20, and 0.001% poly-L-lysine.</p>
</sec>
</sec>
<sec id="section7-1087057111416659">
<title>Data analysis</title>
<p>Data analysis was conducted using the GraphPad Prism 5 software package (GraphPad Software, San Diego, CA). Enzymatic progress curves were fitted using a one-site binding hyperbola equation. SAM and inhibitor concentration–response curves were generated by fitting the data using a four-parameter logistic equation and used for the determination of EC<sub>50</sub> (apparent <italic>K</italic>
<sub>m</sub>) and IC<sub>50</sub> values. Values are expressed as mean of triplicates ± standard deviation. Assay performance and robustness were evaluated using the Z′ factor equation.<sup><xref ref-type="bibr" rid="bibr26-1087057111416659">26</xref></sup></p>
</sec>
</sec>
<sec id="section8-1087057111416659" sec-type="results">
<title>Results</title>
<sec id="section9-1087057111416659">
<title>Assay development workflow</title>
<p>Developing LANCE <italic>Ultra</italic> and AlphaLISA reagents for the immunodetection of defined epigenetic marks requires the careful selection of appropriate antibodies.<sup><xref ref-type="bibr" rid="bibr27-1087057111416659">27</xref></sup> These should allow the sensitive and specific detection of the mark(s) of interest while at the same time minimizing assay background due to cross-reactivity to unmodified substrate molecules. To this end, antibodies recognizing either H3K4me1-2 or unmodified H3K4 were selected and labeled with the LANCE europium chelate W1024 or covalently linked to AlphaLISA acceptor beads using standard protocols. The specificity of the resulting conjugates was characterized in titration experiments using histone H3-derived peptides and full-length histone H3 proteins bearing appropriate epigenetic marks (<bold>Suppl. Fig. S1</bold>). Interestingly, although the anti-unmodified lysine 4 histone H3 antibody was highly specific for the cognate sequence, the anti-methyl lysine 4 antibody was able to detect with similar sensitivity both the mono- and dimethylated forms of histone H3 lysine 4 (H3K4me1-2).</p>
<p>The goal of our enzymatic assay development process was to develop and optimize robust and sensitive assays that can be used for the identification of compounds modulating enzyme activity. The first step of assay development consisted of selecting a substrate concentration between the EC<sub>60</sub> and EC<sub>90</sub> values taken from substrate titration curves. This allowed maximizing enzyme velocity while eliminating the risk of “hooking” on the substrate. A “hook” effect is usually observed in three-component assays when substrate concentrations exceed the binding capacity of the system.<sup><xref ref-type="bibr" rid="bibr28-1087057111416659">28</xref></sup> Following determination of optimal substrate concentration, enzyme progress curves were generated at increasing enzyme concentrations in the presence of saturating cofactor (when required). An enzyme concentration and reaction time providing a linear signal increase over time were selected and used for all subsequent experiments. For methyltransferase assays, SAM titration curves were performed next, at the selected enzyme, substrate, and incubation time conditions. SAM concentrations near the apparent <italic>K</italic>
<sub>m</sub> values were further selected in order for the assays to be sensitive to SAM-competitive inhibitors. Assay linearity was then reconfirmed prior to assessing DMSO tolerance and performing inhibitor concentration–response curves, as well as Z′ factor determination.</p>
</sec>
<sec id="section10-1087057111416659">
<title>SET7/9 methyltransferase assay using a histone H3 peptide substrate</title>
<p>Using a biotinylated histone H3 (1–21) peptide substrate, LANCE <italic>Ultra</italic> and AlphaLISA SET7/9 methyltransferase assays were optimized following the steps described above. Based on peptide titration data (not shown), 200 nM and 50 nM peptide substrate were selected for the LANCE <italic>Ultra</italic> and AlphaLISA assays, respectively. Enzyme progress curves were generated (<xref ref-type="fig" rid="fig2-1087057111416659"><bold>Fig. 2A</bold></xref>,<xref ref-type="fig" rid="fig2-1087057111416659"><bold>B</bold></xref>), and a 60-min reaction time using 5 nM SET7/9 was selected for LANCE <italic>Ultra</italic>, whereas a 30-min reaction time using 1 nM enzyme was chosen for AlphaLISA experiments. The effect of SAM concentration on the methyltransferase activity was then investigated, where both LANCE <italic>Ultra</italic> and AlphaLISA assays showed equivalent apparent <italic>K</italic>
<sub>m</sub> concentrations for SAM, being 75 and 79 nM, respectively (<xref ref-type="fig" rid="fig2-1087057111416659"><bold>Fig. 2C</bold></xref>,<xref ref-type="fig" rid="fig2-1087057111416659"><bold>D</bold></xref>). These values are significantly lower than what has been reported in the literature for SET7/9 assays conducted with H3-derived peptides (17 µM; see Ibañez et al.<sup><xref ref-type="bibr" rid="bibr29-1087057111416659">29</xref></sup>). However, it should be noted that in the Ibañez et al.<sup><xref ref-type="bibr" rid="bibr29-1087057111416659">29</xref></sup> assay protocol, much higher SET7/9 enzyme and peptide substrate concentrations (200- to 1000-fold) were used, a difference that might account for this discrepancy.</p>
<fig id="fig2-1087057111416659" position="float">
<label>Figure 2.</label>
<caption>
<p>LANCE <italic>Ultra</italic> and AlphaLISA SET7/9 methyltransferase assay optimization using a biotinylated histone H3 peptide substrate. (<bold>A, B</bold>) Enzymatic progress curves. Enzymatic progress curves were run at increasing SET7/9 concentrations and stopped at the indicated time points. Peptide substrate and S-adenosyl-L-methionine (SAM) concentrations were (<bold>A</bold>) 200 nM and 300 µM, respectively, for the LANCE <italic>Ultra</italic> assay and (<bold>B</bold>) 50 nM and 100 µM for the AlphaLISA assay. (<bold>C, D</bold>) Determination of the apparent <italic>K</italic><sub>m</sub> (<italic>K</italic><sub>m</sub> app) value for SAM. Enzymatic reactions were carried out at increasing SAM concentrations using (<bold>C</bold>) 5 nM enzyme, 200 nM peptide substrate, and a 60-min incubation time in the LANCE <italic>Ultra</italic> setup and (<bold>D</bold>) 1 nM enzyme, 50 nM peptide substrate, and a 30-min incubation time in the AlphaLISA setup. (<bold>E, F</bold>) Inhibition of SET7/9 methyltransferase activity. Increasing concentrations of inhibitor were preincubated 10 min with the enzyme prior to initiating the methyltransferase reaction with a mixture of peptide substrate and SAM cofactor. Enzymatic reactions were carried out in the presence of 1% DMSO using (<bold>E</bold>) 5 nM enzyme, 200 nM peptide substrate, 300 nM SAM, and a 60-min incubation time in the LANCE <italic>Ultra</italic> setup and (<bold>F</bold>) 1 nM enzyme, 50 nM peptide substrate, 100 nM SAM, and a 30-min incubation time in the AlphaLISA setup. SAH, S-adenosyl-L-homocysteine.</p>
</caption>
<graphic xlink:href="10.1177_1087057111416659-fig2.tif"/></fig>
<p>A concentration of 100 nM SAM (i.e., near the apparent <italic>K</italic><sub>m</sub>) was selected for the AlphaLISA assay, whereas 300 nM (~4× apparent <italic>K</italic><sub>m</sub>) was chosen for LANCE <italic>Ultra</italic> to obtain a larger assay window. Under the selected conditions (summarized in <xref ref-type="table" rid="table1-1087057111416659"><bold>Table 1</bold></xref>), the LANCE <italic>Ultra</italic> assay was linear for up to 60 min (<italic>r</italic><sup>2</sup> = 0.925) with a signal to background (S/B) ratio of 7.3 at 60 min, whereas the AlphaLISA assay was linear for up to 30 min (<italic>r</italic><sup>2</sup> = 0.980) with an S/B ratio of 60 at 30 min (data not shown).</p>
<p>To assess the sensitivity of the LANCE <italic>Ultra</italic> and AlphaLISA assays toward small-molecule modulators, two nonselective SAM-competitive HMT inhibitors were tested: sinefungin, a structural analog of SAM isolated from <italic>Streptomyces</italic>, and SAH, a by-product of all SAM-promoted methyltransferase reactions. Both compounds inhibited SET7/9 activity in a concentration-dependent manner with IC<sub>50</sub> values of 769 and 359 nM for sinefungin and 93 and 16 µM for SAH in the LANCE <italic>Ultra</italic> and AlphaLISA assays, respectively (<xref ref-type="fig" rid="fig2-1087057111416659"><bold>Fig. 2E</bold></xref>,<xref ref-type="fig" rid="fig2-1087057111416659"><bold>F</bold></xref>). The lower IC<sub>50</sub> values obtained with AlphaLISA are consistent with the threefold lower SAM concentration used in the enzymatic reaction. Our data indicate that, under these assay conditions, sinefungin behaves as a more potent inhibitor of SET7/9 than SAH.</p>
<p>Robustness of the optimized LANCE <italic>Ultra</italic> and AlphaLISA assays was determined by evaluating their respective Z′ factor values. Inhibited signal was measured using sinefungin at 300 µM in LANCE <italic>Ultra</italic> and 100 µM for the AlphaLISA assay. Calculated Z′ factor values were above 0.80 with both technologies (<xref ref-type="table" rid="table2-1087057111416659"><bold>Table 2</bold></xref>), with S/B ratios of 9.4 in LANCE <italic>Ultra</italic> and 36 in AlphaLISA. Assay stability was demonstrated for both platforms, with Z′ factor values higher than 0.70 following overnight incubation. Taken together, these results demonstrate the robustness of the optimized SET7/9 methyltransferase peptide assays on both detection platforms and their suitability for HTS.</p>
<table-wrap id="table2-1087057111416659" position="float">
<label>Table 2.</label>
<caption>
<p>Statistical Evaluation of Assay Quality</p>
</caption>
<graphic alternate-form-of="table2-1087057111416659" xlink:href="10.1177_1087057111416659-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">LANCE <italic>Ultra</italic></th>
<th align="center" colspan="2">AlphaLISA</th>
</tr>
<tr>
<th align="left">Enzyme</th>
<th align="center">Z′</th>
<th align="center">S/B</th>
<th align="center">Z′</th>
<th align="center">S/B</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="5">Biotinylated histone H3 peptide substrate</td>
</tr>
<tr>
<td>SET7/9</td>
<td>0.80 (0.86)</td>
<td>9.4 (11)</td>
<td>0.81 (0.71)</td>
<td>36 (20)</td>
</tr>
<tr>
<td>LSD1</td>
<td>0.88 (0.82)</td>
<td> 20 (14)</td>
<td>0.80 (0.83)</td>
<td>643 (262)</td>
</tr>
<tr>
<td colspan="5">Full-length histone H3 substrate</td>
</tr>
<tr>
<td>SET7/9</td>
<td align="center">—</td>
<td align="center">—</td>
<td>0.76 (0.70)</td>
<td>36 (50)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1087057111416659">
<p>Z′ factor values and signal-to-background (S/B) ratios were determined by analyzing 48 assay wells for both total and inhibited signals. The signal was read following a standard 60-min (LANCE <italic>Ultra</italic>) or 30-min (AlphaLISA) incubation with detection reagents. Values in parentheses were obtained following an overnight incubation. See text for details.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section11-1087057111416659">
<title>SET7/9 methyltransferase assay using a full-length histone H3 substrate</title>
<p>In contrast to TR-FRET, the AlphaLISA technology theoretically allows measuring interactions between binding partners over distances up to 250 nm.<sup><xref ref-type="bibr" rid="bibr21-1087057111416659">21</xref></sup> This characteristic makes the Alpha technology a highly suitable tool for developing assays aimed at measuring protein–peptide<sup><xref ref-type="bibr" rid="bibr30-1087057111416659">30</xref>,<xref ref-type="bibr" rid="bibr31-1087057111416659">31</xref></sup> and protein–protein<sup><xref ref-type="bibr" rid="bibr32-1087057111416659">32</xref></sup> interactions, as well as enabling the detection of full-length proteins bearing specific posttranslational modifications.<sup><xref ref-type="bibr" rid="bibr23-1087057111416659">23</xref>,<xref ref-type="bibr" rid="bibr32-1087057111416659">32</xref></sup> The AlphaLISA platform was thus selected for developing a SET7/9 methyltransferase assay using recombinant full-length histone H3 as substrate. The use of detection buffers optimized for short histone H3-derived peptide substrates led to high background levels and a concomitant loss of antibody specificity. Further buffer optimization experiments (not shown) proved that high salt concentration was essential to minimize assay background, whereas the addition of a higher concentration of poly-L-lysine was required to stop the enzymatic reaction. In this regard, the exact mechanism of action of poly-L-lysine as an inhibitor of SET7/9 is not known and was not further studied. However, it could be hypothesized that the addition of a large amount of nonmodified lysine residues will successfully outcompete the ones present on a given substrate, hence bringing its enzymatic modification to a halt. A buffer solution combining both 1 M NaCl and 0.3% poly-L-lysine was thus used to stop the enzymatic reactions prior to the addition of acceptor beads and biotinylated antihistone H3 (C-ter) antibody. With these protocol adjustments in place, development and optimization of the SET7/9 protein assay were resumed through experiments similar to those performed for the SET7/9 assay using biotinylated peptide substrate.</p>
<p>To determine the optimal substrate concentration to be used in the assay, full-length histone H3 titration experiments were performed and a concentration of 300 nM histone H3 protein was selected for further assay optimization (data not shown). Enzyme progress curves were then performed at different SET7/9 concentrations (<xref ref-type="fig" rid="fig3-1087057111416659"><bold>Fig. 3A</bold></xref>). These curves showed a decline of SET7/9 activity over time, with almost no residual activity after 15 min. On the basis of these results, we selected a reaction time of 10 min, using an enzyme concentration of 0.3 nM.</p>
<fig id="fig3-1087057111416659" position="float">
<label>Figure 3.</label>
<caption>
<p>AlphaLISA SET7/9 methyltransferase assay optimization using full-length histone H3 protein substrate. (<bold>A</bold>) Enzymatic progress curves. Enzymatic progress curves were run at increasing SET7/9 concentrations and stopped at the indicated time points. Protein substrate and S-adenosyl-L-methionine (SAM) concentrations were 300 nM and 100 µM, respectively. (<bold>B</bold>) Determination of the apparent (app) <italic>K</italic><sub>m</sub> value for SAM. Enzymatic reactions were carried out at increasing SAM concentrations using 0.3 nM enzyme, 300 nM protein substrate, and a 10-min incubation time. (<bold>C</bold>) Inhibition of SET7/9 methyltransferase activity. Increasing concentrations of inhibitor were preincubated 10 min with the enzyme prior to initiating the methyltransferase reaction with a mixture of protein substrate and SAM cofactor. Enzymatic reactions were carried out in the presence of 1% DMSO, using 0.3 nM enzyme, 300 nM protein substrate, 10 µM SAM, and a 10-min incubation time. SAH, S-adenosyl-L-homocysteine.</p>
</caption>
<graphic xlink:href="10.1177_1087057111416659-fig3.tif"/></fig>
<p>The apparent <italic>K</italic><sub>m</sub> value for SAM was then evaluated at the selected enzyme concentration and incubation time (<xref ref-type="fig" rid="fig3-1087057111416659"><bold>Fig. 3B</bold></xref>). A value of 12 µM was obtained, which is in agreement with literature data (6 µM, Trievel et al.<sup><xref ref-type="bibr" rid="bibr15-1087057111416659">15</xref></sup>; 3.5 µM, Dirk et al.<sup><xref ref-type="bibr" rid="bibr33-1087057111416659">33</xref></sup>). A concentration of 10 µM SAM was selected for the optimized protein assay. Interestingly, this apparent <italic>K</italic><sub>m</sub> value is considerably higher than the one obtained for the AlphaLISA peptide assay (79 nM), a fact that could be attributable to the different nature of the substrates. Linearity of the optimized enzymatic reaction as a function of time was then confirmed for up to 10 min (<italic>r</italic><sup>2</sup> = 0.941) with an S/B ratio of 29 (data not shown). Optimized assay conditions are summarized in <xref ref-type="table" rid="table1-1087057111416659"><bold>Table 1</bold></xref>.</p>
<p>Concentration–response curves for sinefungin and SAH were performed, and both compounds inhibited SET7/9 activity with IC<sub>50</sub> values of 47 µM for sinefungin and 175 µM for SAH (<xref ref-type="fig" rid="fig3-1087057111416659"><bold>Fig. 3C</bold></xref>). As expected, IC<sub>50</sub> values were higher than those obtained in the SET7/9 methyltransferase peptide assay because a higher SAM concentration was used for the protein assay. However, the same rank order of potency was obtained for the two compounds regardless of the substrate used (<xref ref-type="fig" rid="fig2-1087057111416659"><bold>Figs. 2F</bold></xref> and <xref ref-type="fig" rid="fig3-1087057111416659"><bold>3C</bold></xref>). A Z′ factor value of 0.76 with an S/B ratio of 36 were obtained using 10 mM sinefungin for inhibited samples and, importantly, performance was maintained after an overnight incubation (<xref ref-type="table" rid="table2-1087057111416659"><bold>Table 2</bold></xref>). These results confirm the AlphaLISA SET7/9 methyltransferase protein assay robustness as well as its suitability for HTS.</p>
</sec>
<sec id="section12-1087057111416659">
<title>LSD1 demethylase assay using a H3K4me1 peptide substrate</title>
<p>The availability of LANCE <italic>Ultra</italic> and AlphaLISA reagents specifically detecting unmethylated lysine 4 allowed developing LSD1 demethylase signal increase assays measuring the appearance of the demethylated product. Because LSD1 has been reported to demethylate monomethyl-lysine 4 on histone H3-derived peptides at least 20 residues long,<sup><xref ref-type="bibr" rid="bibr19-1087057111416659">19</xref></sup> a biotinylated H3K4me1 peptide (residues 1–21) was selected as substrate for these assays. Following titration of the H3K4me1 peptide, a concentration of 200 nM was chosen for LANCE <italic>Ultra</italic> and 80 nM for AlphaLISA assays (data not shown). Enzyme progress curves showed that signal increased linearly with time for up to 2 h when 2 nM LSD1 was used (<xref ref-type="fig" rid="fig4-1087057111416659"><bold>Fig. 4A</bold></xref>,<xref ref-type="fig" rid="fig4-1087057111416659"><bold>B</bold></xref>). On the basis of these results, we selected a 60-min reaction time and a 2-nM LSD1 enzyme concentration for the subsequent experiments with both technologies (<xref ref-type="table" rid="table1-1087057111416659"><bold>Table 1</bold></xref>). Under these conditions, S/B ratios were equal to 18 and 292 for LANCE <italic>Ultra</italic> and AlphaLISA assays, respectively. The redox cofactor FAD is essential for LSD1 activity and is strongly embedded in the amine oxidase domain. As such, FAD addition to the enzyme reaction buffer is not necessary for optimal enzymatic activity as it is already present in recombinant LSD1 enzyme preparations.<sup><xref ref-type="bibr" rid="bibr10-1087057111416659">10</xref></sup></p>
<fig id="fig4-1087057111416659" position="float">
<label>Figure 4.</label>
<caption>
<p>LANCE <italic>Ultra</italic> and AlphaLISA LSD1 demethylase assay optimization using biotinylated H3K4me1 peptide substrate. (<bold>A, B</bold>) Enzymatic progress curves. Enzymatic progress curves were run at increasing LSD1 concentrations and stopped at the indicated time points. Peptide substrate concentrations were (<bold>A</bold>) 200 nM for the LANCE <italic>Ultra</italic> assay and (<bold>B</bold>) 80 nM for the AlphaLISA assay. (<bold>C, D</bold>) Inhibition of LSD1 demethylase activity. Increasing concentrations of inhibitor were preincubated 10 min with the enzyme prior to initiating the demethylase reaction with the peptide substrate. Enzymatic reactions were carried out in the presence of 1% DMSO using (<bold>C</bold>) 2 nM enzyme, 200 nM peptide substrate, and a 60-min incubation time in the LANCE <italic>Ultra</italic> setup and (<bold>D</bold>) 2 nM enzyme, 80 nM peptide substrate, and a 60-min incubation time in the AlphaLISA setup.</p>
</caption>
<graphic xlink:href="10.1177_1087057111416659-fig4.tif"/></fig>
<p>The antidepressant drug tranylcypromine is a monoamine oxidase inhibitor reported to inhibit the activity of LSD1 demethylase.<sup><xref ref-type="bibr" rid="bibr34-1087057111416659">34</xref></sup> Data in <xref ref-type="fig" rid="fig4-1087057111416659"><bold>Figure 4C</bold></xref>,<xref ref-type="fig" rid="fig4-1087057111416659"><bold>D</bold></xref> indicate that tranylcypromine inhibits LSD1 enzyme activity in a concentration-dependent manner with similar IC<sub>50</sub> values of 74 and 32 µM for the LANCE <italic>Ultra</italic> and AlphaLISA assays, respectively. Given that tranylcypromine is an irreversible covalent inhibitor of enzyme activity, comparison of IC<sub>50</sub> values reported herein with those published in the literature has not been performed due to significant differences in assay conditions. Finally, assay robustness was assessed by Z′ factor determination, where inhibited signal was measured using 3 mM tranylcypromine. Values of 0.88 and 0.80 were obtained, with S/B ratios of 20 and 643 for LANCE <italic>Ultra</italic> and AlphaLISA assays, respectively, demonstrating their suitability for HTS (<xref ref-type="table" rid="table2-1087057111416659"><bold>Table 2</bold></xref>).</p>
</sec>
</sec>
<sec id="section13-1087057111416659" sec-type="discussion">
<title>Discussion</title>
<p>In this study, we presented the development and optimization of LANCE <italic>Ultra</italic> and AlphaLISA assays for two epigenetic enzymes controlling the methylation state of histone H3 lysine 4 residues. Optimized assays were highly sensitive, requiring low enzyme and substrate concentrations, which confers a significant advantage in terms of cost over less sensitive methods as liquid chromatography/mass spectrometry or enzyme-coupled assays. Importantly, the use of low nanomolar enzyme concentrations can enable structure–activity relationship studies where the use of very low concentrations of small-molecule compounds is required. Our assays also allowed inhibitor profiling and were highly robust, as highlighted by Z′ factor values equal or above 0.7. Notably, assay quality was maintained following an overnight incubation, allowing both online and off-line plate reading.</p>
<p>Although the presented data focused on the development of SET7/9 and LSD1 assays, the same antimark specific detection reagents could also be used for studying other enzymes involved in the modification of the H3K4 residue. For instance, a signal increase SIRT1 assay measuring the deacetylation of H3K4 residues has been optimized using reagents detecting unmodified H3K4 (unpublished data). Similarly, demethylation of an H3K4 trimethylated substrate could also be monitored using either the H3K4me1-2 or unmodified H3K4 detection reagents. In brief, the assay development approach described here is broadly applicable to other epigenetic marks and in fact has been used for developing LANCE <italic>Ultra</italic> and AlphaLISA reagents detecting H3K9me2, H3K9ac, H3K27ac, H3K27me1-2, H3K27me3, and H3K36me2 (unpublished data). This could aid in the identification of novel small-molecule compounds of pharmacological value targeting important epigenetic enzymes such as EZH2, the Jumonji domain–containing family of demethylases, acetyltransferases such as p300 and pCAF, and deacetylases from the HDAC and sirtuin classes.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="other">
<p>All authors are employees of PerkinElmer. None of the authors or PerkinElmer received at any time payment or services from a third party for any aspect of the submitted work. There are no other relationships/conditions/circumstances that present a potential conflict of interest.</p>
</fn>
<fn fn-type="supplementary-material">
<p>Supplementary material for this article is available on the <italic>Journal of Biomolecular Screening</italic> Web site at <ext-link ext-link-type="uri" xlink:href="http://jbx.sagepub.com/supplemental">http://jbx.sagepub.com/supplemental</ext-link>.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1087057111416659">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bannister</surname><given-names>A. J.</given-names></name>
<name><surname>Kouzarides</surname><given-names>T.</given-names></name>
</person-group> <article-title>Regulation of Chromatin by Histone Modifications</article-title>. <source>Cell Res.</source> <year>2011</year>, <volume>21</volume>, <fpage>381</fpage>–<lpage>395</lpage>.</citation>
</ref>
<ref id="bibr2-1087057111416659">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shi</surname><given-names>Y.</given-names></name>
<name><surname>Whetstine</surname><given-names>J. R.</given-names></name>
</person-group> <article-title>Dynamic Regulation of Histone Lysine Methylation by Demethylases</article-title>. <source>Mol. Cell</source> <year>2007</year>, <volume>25</volume>, <fpage>1</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr3-1087057111416659">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chi</surname><given-names>P.</given-names></name>
<name><surname>Allis</surname><given-names>C. D.</given-names></name>
<name><surname>Wang</surname><given-names>G. G.</given-names></name>
</person-group> <article-title>Covalent Histone Modifications—Miswritten, Misinterpreted and Mis-erased in Human Cancers</article-title>. <source>Nat. Rev. Cancer</source> <year>2010</year>, <volume>10</volume>, <fpage>457</fpage>–<lpage>469</lpage>.</citation>
</ref>
<ref id="bibr4-1087057111416659">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Urdinguio</surname><given-names>R. G.</given-names></name>
<name><surname>Sanchez-Mut</surname><given-names>J. V.</given-names></name>
<name><surname>Esteller</surname><given-names>M.</given-names></name>
</person-group> <article-title>Epigenetic Mechanisms in Neurological Diseases: Genes, Syndromes, and Therapies</article-title>. <source>Lancet Neurol.</source> <year>2009</year>, <volume>8</volume>, <fpage>1056</fpage>–<lpage>1072</lpage>.</citation>
</ref>
<ref id="bibr5-1087057111416659">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kelly</surname><given-names>T. K.</given-names></name>
<name><surname>De Carvalho</surname><given-names>D. D.</given-names></name>
<name><surname>Jones</surname><given-names>P. A.</given-names></name>
</person-group> <article-title>Epigenetic Modifications as Therapeutic Targets</article-title>. <source>Nat. Biotechnol.</source> <year>2010</year>, <volume>28</volume>, <fpage>1069</fpage>–<lpage>1078</lpage>.</citation>
</ref>
<ref id="bibr6-1087057111416659">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruthenburg</surname><given-names>A. J.</given-names></name>
<name><surname>Allis</surname><given-names>C. D.</given-names></name>
<name><surname>Wysocka</surname><given-names>J.</given-names></name>
</person-group> <article-title>Methylation of Lysine 4 on Histone H3: Intricacy of Writing and Reading a Single Epigenetic Mark</article-title>. <source>Mol. Cell</source> <year>2007</year>, <volume>25</volume>, <fpage>15</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr7-1087057111416659">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Cao</surname><given-names>R.</given-names></name>
<name><surname>Xia</surname><given-names>L.</given-names></name>
<name><surname>Erdjument-Bromage</surname><given-names>H.</given-names></name>
<name><surname>Borchers</surname><given-names>C.</given-names></name>
<name><surname>Tempst</surname><given-names>P.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
</person-group> <article-title>Purification and Functional Characterization of a Histone H3-Lysine 4-Specific Methyltransferase</article-title>. <source>Mol. Cell</source> <year>2001</year>, <volume>8</volume>, <fpage>1207</fpage>–<lpage>1217</lpage>.</citation>
</ref>
<ref id="bibr8-1087057111416659">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nishioka</surname><given-names>K.</given-names></name>
<name><surname>Chuikov</surname><given-names>S.</given-names></name>
<name><surname>Sarma</surname><given-names>K.</given-names></name>
<name><surname>Erdjument-Bromage</surname><given-names>H.</given-names></name>
<name><surname>Allis</surname><given-names>C. D.</given-names></name>
<name><surname>Tempst</surname><given-names>P.</given-names></name>
<name><surname>Reinberg</surname><given-names>D.</given-names></name>
</person-group> <article-title>Set9, a Novel Histone H3 Methyltransferase That Facilitates Transcription by Precluding Histone Tail Modifications Required for Heterochromatin Formation</article-title>. <source>Genes Dev.</source> <year>2002</year>, <volume>16</volume>, <fpage>479</fpage>–<lpage>489</lpage>.</citation>
</ref>
<ref id="bibr9-1087057111416659">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Milne</surname><given-names>T. A.</given-names></name>
<name><surname>Briggs</surname><given-names>S. D.</given-names></name>
<name><surname>Brock</surname><given-names>H. W.</given-names></name>
<name><surname>Martin</surname><given-names>M. E.</given-names></name>
<name><surname>Gibbs</surname><given-names>D.</given-names></name>
<name><surname>Allis</surname><given-names>C. D.</given-names></name>
<name><surname>Hess</surname><given-names>J. L.</given-names></name>
</person-group> <article-title>MLL Targets SET Domain Methyltransferase Activity to Hox Gene Promoters</article-title>. <source>Mol. Cell</source> <year>2002</year>, <volume>10</volume>, <fpage>1107</fpage>–<lpage>1117</lpage>.</citation>
</ref>
<ref id="bibr10-1087057111416659">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shi</surname><given-names>Y.</given-names></name>
<name><surname>Lan</surname><given-names>F.</given-names></name>
<name><surname>Matson</surname><given-names>C.</given-names></name>
<name><surname>Mulligan</surname><given-names>P.</given-names></name>
<name><surname>Whetstine</surname><given-names>J. R.</given-names></name>
<name><surname>Cole</surname><given-names>P. A.</given-names></name>
<name><surname>Casero</surname><given-names>R. A.</given-names></name>
<name><surname>Shi</surname><given-names>Y.</given-names></name>
</person-group> <article-title>Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1</article-title>. <source>Cell</source> <year>2004</year>, <volume>119</volume>, <fpage>941</fpage>–<lpage>953</lpage>.</citation>
</ref>
<ref id="bibr11-1087057111416659">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xiao</surname><given-names>B.</given-names></name>
<name><surname>Jing</surname><given-names>C.</given-names></name>
<name><surname>Wilson</surname><given-names>J. R.</given-names></name>
<name><surname>Walker</surname><given-names>P. A.</given-names></name>
<name><surname>Vasisht</surname><given-names>N.</given-names></name>
<name><surname>Kelly</surname><given-names>G.</given-names></name>
<name><surname>Howell</surname><given-names>S.</given-names></name>
<name><surname>Taylor</surname><given-names>I. A.</given-names></name>
<name><surname>Blackburn</surname><given-names>G. M.</given-names></name>
<name><surname>Gamblin</surname><given-names>S. J.</given-names></name>
</person-group> <article-title>Structure and Catalytic Mechanism of the Human Histone Methyltransferase SET7/9</article-title>. <source>Nature</source> <year>2003</year>, <volume>421</volume>, <fpage>652</fpage>–<lpage>656</lpage>.</citation>
</ref>
<ref id="bibr12-1087057111416659">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Metzger</surname><given-names>E.</given-names></name>
<name><surname>Wissmann</surname><given-names>M.</given-names></name>
<name><surname>Yin</surname><given-names>N.</given-names></name>
<name><surname>Muller</surname><given-names>J. M.</given-names></name>
<name><surname>Schneider</surname><given-names>R.</given-names></name>
<name><surname>Peters</surname><given-names>A. H.</given-names></name>
<name><surname>Günther</surname><given-names>T.</given-names></name>
<name><surname>Buettner</surname><given-names>R.</given-names></name>
<name><surname>Schüle</surname><given-names>R.</given-names></name>
</person-group> <article-title>LSD1 Demethylates Repressive Histone Marks to Promote Androgen-Receptor-Dependent Transcription</article-title>. <source>Nature</source> <year>2005</year>, <volume>437</volume>, <fpage>436</fpage>–<lpage>439</lpage>.</citation>
</ref>
<ref id="bibr13-1087057111416659">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Reddy</surname><given-names>M. A.</given-names></name>
<name><surname>Miao</surname><given-names>F.</given-names></name>
<name><surname>Shanmugam</surname><given-names>N.</given-names></name>
<name><surname>Yee</surname><given-names>J. K.</given-names></name>
<name><surname>Hawkins</surname><given-names>D.</given-names></name>
<name><surname>Ren</surname><given-names>B.</given-names></name>
<name><surname>Natarajan</surname><given-names>R.</given-names></name>
</person-group> <article-title>Role of the Histone H3 Lysine 4 Methyltransferase, SET7/9, in the Regulation of NF-kappaB-Dependent Inflammatory Genes: Relevance to Diabetes and Inflammation</article-title>. <source>J. Biol. Chem.</source> <year>2008</year>, <volume>283</volume>, <fpage>26771</fpage>–<lpage>26781</lpage>.</citation>
</ref>
<ref id="bibr14-1087057111416659">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hayami</surname><given-names>S.</given-names></name>
<name><surname>Kelly</surname><given-names>J. D.</given-names></name>
<name><surname>Cho</surname><given-names>H. S.</given-names></name>
<name><surname>Yoshimatsu</surname><given-names>M.</given-names></name>
<name><surname>Unoki</surname><given-names>M.</given-names></name>
<name><surname>Tsunoda</surname><given-names>T.</given-names></name>
<name><surname>Field</surname><given-names>H. I.</given-names></name>
<name><surname>Neal</surname><given-names>D. E.</given-names></name>
<name><surname>Yamaue</surname><given-names>H.</given-names></name>
<name><surname>Ponder</surname><given-names>B. A.</given-names></name>
</person-group> <article-title>Overexpression of LSD1 Contributes to Human Carcinogenesis through Chromatin Regulation in Various Cancers</article-title>. <source>Int. J. Cancer</source> <year>2011</year>, <volume>128</volume>, <fpage>574</fpage>–<lpage>586</lpage>.</citation>
</ref>
<ref id="bibr15-1087057111416659">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Trievel</surname><given-names>R. C.</given-names></name>
<name><surname>Beach</surname><given-names>B. M.</given-names></name>
<name><surname>Dirk</surname><given-names>L. M.</given-names></name>
<name><surname>Houtz</surname><given-names>R. L.</given-names></name>
<name><surname>Hurley</surname><given-names>J. H.</given-names></name>
</person-group> <article-title>Structure and Catalytic Mechanism of a SET Domain Protein Methyltransferase</article-title>. <source>Cell</source> <year>2002</year>, <volume>111</volume>, <fpage>91</fpage>–<lpage>103</lpage>.</citation>
</ref>
<ref id="bibr16-1087057111416659">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dhayalan</surname><given-names>A.</given-names></name>
<name><surname>Dimitrova</surname><given-names>E.</given-names></name>
<name><surname>Rathert</surname><given-names>P.</given-names></name>
<name><surname>Jeltsch</surname><given-names>A.</given-names></name>
</person-group> <article-title>A Continuous Protein Methyltransferase (G9a) Assay for Enzyme Activity Measurement and Inhibitor Screening</article-title>. <source>J. Biomol. Screen.</source> <year>2009</year>, <volume>14</volume>, <fpage>1129</fpage>–<lpage>1133</lpage>.</citation>
</ref>
<ref id="bibr17-1087057111416659">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kubicek</surname><given-names>S.</given-names></name>
<name><surname>O’Sullivan</surname><given-names>R. J.</given-names></name>
<name><surname>August</surname><given-names>E. M.</given-names></name>
<name><surname>Hickey</surname><given-names>E. R.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Teodoro</surname><given-names>M. L.</given-names></name>
<name><surname>Rea</surname><given-names>S.</given-names></name>
<name><surname>Mechtler</surname><given-names>K.</given-names></name>
<name><surname>Kowalski</surname><given-names>J. A.</given-names></name>
<name><surname>Homon</surname><given-names>C. A.</given-names></name>
<etal/>
</person-group>. <article-title>Reversal of H3K9me2 by a Small-Molecule Inhibitor for the G9a Histone Methyltransferase</article-title>. <source>Mol. Cell</source> <year>2007</year>, <volume>25</volume>, <fpage>473</fpage>–<lpage>481</lpage>.</citation>
</ref>
<ref id="bibr18-1087057111416659">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Collazo</surname><given-names>E.</given-names></name>
<name><surname>Couture</surname><given-names>J. F.</given-names></name>
<name><surname>Bulfer</surname><given-names>S.</given-names></name>
<name><surname>Trievel</surname><given-names>R. C.</given-names></name>
</person-group> <article-title>A Coupled Fluorescent Assay for Histone Methyltransferases</article-title>. <source>Anal. Biochem.</source> <year>2005</year>, <volume>342</volume>, <fpage>86</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr19-1087057111416659">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Forneris</surname><given-names>F.</given-names></name>
<name><surname>Binda</surname><given-names>C.</given-names></name>
<name><surname>Vanoni</surname><given-names>M. A.</given-names></name>
<name><surname>Battaglioli</surname><given-names>E.</given-names></name>
<name><surname>Mattevi</surname><given-names>A.</given-names></name>
</person-group> <article-title>Human Histone Demethylase LSD1 Reads the Histone Code</article-title>. <source>J. Biol. Chem.</source> <year>2005</year>, <volume>280</volume>, <fpage>41360</fpage>–<lpage>41365</lpage>.</citation>
</ref>
<ref id="bibr20-1087057111416659">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hemmilä</surname><given-names>I.</given-names></name>
</person-group> <article-title>LANCE™: Homogeneous Assay Platform for HTS</article-title>. <source>J. Biomol. Screen.</source> <year>1999</year>, <volume>4</volume>, <fpage>303</fpage>–<lpage>308</lpage>.</citation>
</ref>
<ref id="bibr21-1087057111416659">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ullman</surname><given-names>E. F.</given-names></name>
<name><surname>Kirakossian</surname><given-names>H.</given-names></name>
<name><surname>Switchenko</surname><given-names>A. C.</given-names></name>
<name><surname>Ishkanian</surname><given-names>J.</given-names></name>
<name><surname>Ericson</surname><given-names>M.</given-names></name>
<name><surname>Wartchow</surname><given-names>C. A.</given-names></name>
<name><surname>Pirio</surname><given-names>M.</given-names></name>
<name><surname>Pease</surname><given-names>J.</given-names></name>
<name><surname>Irvin</surname><given-names>B. R.</given-names></name>
<name><surname>Singh</surname><given-names>S.</given-names></name><etal/>
</person-group>. <article-title>Luminescent Oxygen Channeling Assay (LOCI): Sensitive, Broadly Applicable Homogeneous Immunoassay Method</article-title>. <source>Clin. Chem.</source> <year>1996</year>, <volume>42</volume>, <fpage>1518</fpage>–<lpage>1526</lpage>.</citation>
</ref>
<ref id="bibr22-1087057111416659">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eglen</surname><given-names>R. M.</given-names></name>
<name><surname>Reisine</surname><given-names>T.</given-names></name>
<name><surname>Roby</surname><given-names>P.</given-names></name>
<name><surname>Rouleau</surname><given-names>N.</given-names></name>
<name><surname>Illy</surname><given-names>C.</given-names></name>
<name><surname>Bosse</surname><given-names>R.</given-names></name>
<name><surname>Bielefeld</surname><given-names>M.</given-names></name>
</person-group> <article-title>The Use of AlphaScreen Technology in HTS: Current Status</article-title>. <source>Curr. Chem. Genomics</source> <year>2008</year>, <volume>1</volume>, <fpage>2</fpage>–<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr23-1087057111416659">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pedro</surname><given-names>L.</given-names></name>
<name><surname>Padros</surname><given-names>J.</given-names></name>
<name><surname>Beaudet</surname><given-names>L.</given-names></name>
<name><surname>Schubert</surname><given-names>H. D.</given-names></name>
<name><surname>Gillardon</surname><given-names>F.</given-names></name>
<name><surname>Dahan</surname><given-names>S.</given-names></name>
</person-group> <article-title>Development of a High-Throughput AlphaScreen Assay Measuring Full-Length LRRK2(G2019S) Kinase Activity Using Moesin Protein Substrate</article-title>. <source>Anal. Biochem.</source> <year>2010</year>, <volume>404</volume>, <fpage>45</fpage>–<lpage>51</lpage>.</citation>
</ref>
<ref id="bibr24-1087057111416659">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Quinn</surname><given-names>A. M.</given-names></name>
<name><surname>Allali-Hassani</surname><given-names>A.</given-names></name>
<name><surname>Vedadi</surname><given-names>M.</given-names></name>
<name><surname>Simeonov</surname><given-names>A.</given-names></name>
</person-group> <article-title>A Chemiluminescence-Based Method for Identification of Histone Lysine Methyltransferase Inhibitors</article-title>. <source>Mol. Biosyst.</source> <year>2010</year>, <volume>6</volume>, <fpage>782</fpage>–<lpage>788</lpage>.</citation>
</ref>
<ref id="bibr25-1087057111416659">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kawamura</surname><given-names>A.</given-names></name>
<name><surname>Tumber</surname><given-names>A.</given-names></name>
<name><surname>Rose</surname><given-names>N. R.</given-names></name>
<name><surname>King</surname><given-names>O. N.</given-names></name>
<name><surname>Daniel</surname><given-names>M.</given-names></name>
<name><surname>Oppermann</surname><given-names>U.</given-names></name>
<name><surname>Heightman</surname><given-names>T. D.</given-names></name>
<name><surname>Schofield</surname><given-names>C.</given-names></name>
</person-group> <article-title>Development of Homogeneous Luminescence Assays for Histone Demethylase Catalysis and Binding</article-title>. <source>Anal. Biochem.</source> <year>2010</year>, <volume>404</volume>, <fpage>86</fpage>–<lpage>93</lpage>.</citation>
</ref>
<ref id="bibr26-1087057111416659">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>J. H.</given-names></name>
<name><surname>Chung</surname><given-names>T. D.</given-names></name>
<name><surname>Oldenburg</surname><given-names>K. R.</given-names></name>
</person-group> <article-title>A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays</article-title>. <source>J. Biomol. Screen.</source> <year>1999</year>, <volume>4</volume>, <fpage>67</fpage>–<lpage>73</lpage>.</citation>
</ref>
<ref id="bibr27-1087057111416659">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fuchs</surname><given-names>S. M.</given-names></name>
<name><surname>Krajewski</surname><given-names>K.</given-names></name>
<name><surname>Baker</surname><given-names>R. W.</given-names></name>
<name><surname>Miller</surname><given-names>V. L.</given-names></name>
<name><surname>Strahl</surname><given-names>B. D.</given-names></name>
</person-group> <article-title>Influence of Combinatorial Histone Modifications on Antibody and Effector Protein Recognition</article-title>. <source>Curr. Biol.</source> <year>2011</year>, <volume>21</volume>, <fpage>53</fpage>–<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr28-1087057111416659">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fernando</surname><given-names>S. A.</given-names></name>
<name><surname>Wilson</surname><given-names>G. S.</given-names></name>
</person-group> <article-title>Studies of the ‘Hook’ Effect in the One-Step Sandwich Immunoassay</article-title>. <source>J. Immunol. Methods</source> <year>1992</year>, <volume>151</volume>, <fpage>47</fpage>–<lpage>66</lpage>.</citation>
</ref>
<ref id="bibr29-1087057111416659">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ibañez</surname><given-names>G.</given-names></name>
<name><surname>Mcbean</surname><given-names>J. L.</given-names></name>
<name><surname>Astudillo</surname><given-names>Y. M.</given-names></name>
<name><surname>Luo</surname><given-names>M.</given-names></name>
</person-group> <article-title>An Enzyme-Coupled Ultrasensitive Luminescence Assay for Protein Methyltransferases</article-title>. <source>Anal. Biochem.</source> <year>2010</year>, <volume>401</volume>, <fpage>203</fpage>–<lpage>210</lpage>.</citation>
</ref>
<ref id="bibr30-1087057111416659">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Quinn</surname><given-names>A. M.</given-names></name>
<name><surname>Bedford</surname><given-names>M. T.</given-names></name>
<name><surname>Espejo</surname><given-names>A.</given-names></name>
<name><surname>Spannhoff</surname><given-names>A.</given-names></name>
<name><surname>Austin</surname><given-names>C. P.</given-names></name>
<name><surname>Oppermann</surname><given-names>U.</given-names></name>
<name><surname>Simeonov</surname><given-names>A.</given-names></name>
</person-group> <article-title>A Homogeneous Method for Investigation of Methylation-Dependent Protein-Protein Interactions in Epigenetics</article-title>. <source>Nucleic Acids Res.</source> <year>2010</year>, <volume>38</volume>, <fpage>e11</fpage>.</citation>
</ref>
<ref id="bibr31-1087057111416659">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wigle</surname><given-names>T. J.</given-names></name>
<name><surname>Herold</surname><given-names>J. M.</given-names></name>
<name><surname>Senisterra</surname><given-names>G. A.</given-names></name>
<name><surname>Vedadi</surname><given-names>M.</given-names></name>
<name><surname>Kireev</surname><given-names>D. B.</given-names></name>
<name><surname>Arrowsmith</surname><given-names>C. H.</given-names></name>
<name><surname>Frye</surname><given-names>S. V.</given-names></name>
<name><surname>Janzen</surname><given-names>W. P.</given-names></name>
</person-group> <article-title>Screening for Inhibitors of Low-Affinity Epigenetic Peptide-Protein Interactions: An AlphaScreen-Based Assay for Antagonists of Methyl-lysine Binding Proteins</article-title>. <source>J. Biomol. Screen.</source> <year>2010</year>, <volume>15</volume>, <fpage>62</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr32-1087057111416659">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arcand</surname><given-names>M.</given-names></name>
<name><surname>Roby</surname><given-names>P.</given-names></name>
<name><surname>Bosse</surname><given-names>R.</given-names></name>
<name><surname>Lipari</surname><given-names>F.</given-names></name>
<name><surname>Padros</surname><given-names>J.</given-names></name>
<name><surname>Beaudet</surname><given-names>L.</given-names></name>
<name><surname>Marcil</surname><given-names>A.</given-names></name>
<name><surname>Dahan</surname><given-names>S.</given-names></name>
</person-group> <article-title>Single-Well Monitoring of Protein-Protein Interaction and Phosphorylation-Dephosphorylation Events</article-title>. <source>Biochemistry</source> <year>2010</year>, <volume>49</volume>, <fpage>3213</fpage>–<lpage>3215</lpage>.</citation>
</ref>
<ref id="bibr33-1087057111416659">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dirk</surname><given-names>L. M.</given-names></name>
<name><surname>Flynn</surname><given-names>E. M.</given-names></name>
<name><surname>Dietzel</surname><given-names>K.</given-names></name>
<name><surname>Couture</surname><given-names>J. F.</given-names></name>
<name><surname>Trievel</surname><given-names>R. C.</given-names></name>
<name><surname>Houtz</surname><given-names>R. L.</given-names></name>
</person-group> <article-title>Kinetic Manifestation of Processivity during Multiple Methylations Catalyzed by SET Domain Protein Methyltransferases</article-title>. <source>Biochemistry</source> <year>2007</year>, <volume>46</volume>, <fpage>3905</fpage>–<lpage>3915</lpage>.</citation>
</ref>
<ref id="bibr34-1087057111416659">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schmidt</surname><given-names>D. M.</given-names></name>
<name><surname>McCafferty</surname><given-names>D. G.</given-names></name>
</person-group> <article-title>Trans-2-Phenylcyclopropylamine is a Mechanism-Based Inactivator of the Histone Demethylase LSD1</article-title>. <source>Biochemistry</source> <year>2007</year>, <volume>46</volume>, <fpage>4408</fpage>–<lpage>4416</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>